Seeking Alpha

Alectinib cleared in Japan

  • The Japanese Ministry of Health, Labor and Welfare approves Roche's (RHHBY) alectinib for the treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). The product will be available for sale later this year.
  • In June 2013, the FDA granted alectinib BTD status for ALK+ NSCLC patients who progress on crizotinib.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: